Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same author

Vitamin A and body weight status do not impact humoral immunity against measles, mumps or rubella in individuals 4 to 18 years old: a cross-sectional cohort study in India.

Vaccine·2026
Same author

Cytomegalovirus serostatus and plasma MCP-1 levels are associated with antibody response to seasonal influenza vaccine across age and sex.

medRxiv : the preprint server for health sciences·2026
Same author

Sex-based differences in mumps immunity after a third dose of measles-mumps-rubella vaccine.

Vaccine·2026
Same author

Seroprevalence of mumps and rubella antibodies among Indian children: evidence of a mumps immunity gap.

Vaccine·2026
Same author

COVID-19 vaccine policy: a response and way forward.

Vaccine·2026

Related Experiment Video

Updated: Jan 2, 2026

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice
10:01

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

8.4K

Zika Vaccine Development: Current Status.

Gregory A Poland1, Inna G Ovsyannikova1, Richard B Kennedy1

  • 1Mayo Clinic Vaccine Research Group, Division of General Internal Medicine, Mayo Clinic, Rochester, MN.

Mayo Clinic Proceedings
|December 7, 2019
PubMed
Summary
This summary is machine-generated.

Developing safe and effective Zika virus vaccines is crucial due to explosive outbreaks. Current vaccine candidates are in clinical trials, but financial investment and overcoming barriers are key to public availability.

More Related Videos

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

21.3K
Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells
07:53

Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells

Published on: January 18, 2019

9.2K

Related Experiment Videos

Last Updated: Jan 2, 2026

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice
10:01

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

8.4K
Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

21.3K
Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells
07:53

Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells

Published on: January 18, 2019

9.2K

Area of Science:

  • Virology
  • Immunology
  • Public Health

Background:

  • Zika virus outbreaks have caused significant health issues and public concern.
  • Multiple candidate vaccines have been developed in response to the Zika threat.

Purpose of the Study:

  • To review current Zika virus vaccine development efforts.
  • To analyze preclinical and clinical results of vaccine candidates.
  • To discuss ethical and practical barriers to vaccine licensure and availability.

Main Methods:

  • Literature review of current Zika vaccine research.
  • Survey of preclinical and clinical trial data.
  • Analysis of ethical considerations and financial investment challenges.

Main Results:

  • Several Zika vaccine candidates are progressing through clinical development, with some in Phase 2 trials.
  • Preclinical and clinical data are being generated for multiple vaccine platforms.
  • Significant financial investment and overcoming regulatory and ethical hurdles are critical.

Conclusions:

  • Safe and effective Zika virus vaccines are urgently needed.
  • The successful licensure and public availability of Zika vaccines depend on sustained financial commitment and addressing development barriers.